tbuckley/cabot-search huggingface dataset:
Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy
Authors: Alberto Iannalfi, Emma D’Ippolito, Giulia Riva, Silvia Molinelli, Sara Gandini, Gisela Viselner, Maria Rosaria Fiore, Barbara Vischioni, Viviana Vitolo, Maria Bonora, Sara Ronchi, Rachele Petrucci, Amelia Barcellini, Alfredo Mirandola, Stefania Russo, Alessandro Vai, Edoardo Mastella, Giuseppe Magro, Davide Maestri, Mario Ciocca, Lorenzo Preda, Francesca Valvo, Roberto Orecchia
Journal: Neuro-Oncology (2020)

The aim of this study is to evaluate results in terms of local control (LC), overall survival (OS), and toxicity profile and to better identify factors influencing clinical outcome of skull base chordoma treated with proton therapy (PT) and carbon ion radiotherapy (CIRT).We prospectively collected and analyzed data of 135 patients treated between November 2011 and December 2018. Total prescription dose in the PT group (70 patients) and CIRT group (65 patients) was 74 Gy relative biological effectiveness (RBE) delivered in 37 fractions and 70.4 Gy(RBE) delivered in 16 fractions, respectively (CIRT in unfavorable patients). LC and OS were evaluated using the Kaplan-Meier method. Univariate and multivariate analyses were performed, to identify prognostic factors on clinical outcomes.After a median follow-up of 44 (range, 6-87) months, 14 (21%) and 8 (11%) local failures were observed in CIRT and PT group, respectively. Five-year LC rate was 71% in CIRT cohort and 84% in PT cohort. The estimated 5-year OS rate in the CIRT and PT group was 82% and 83%, respectively. On multivariate analysis, gross tumor volume (GTV), optic pathways, and/or brainstem compression and dose coverage are independent prognostic factors of local failure risk. High rate toxicity grade ≥3 was reported in 11% of patients.Particle radiotherapy is an effective treatment for skull base chordoma with acceptable late toxicity. GTV, optic pathways, and/or brainstem compression and target coverage were independent prognostic factors for LC.• Proton and carbon ion therapy are effective and safe in skull base chordoma.• Prognostic factors are GTV, organs at risk compression, and dose coverage.• Dual particle therapy and customized strategy was adopted.
COMPARATIVE RADIATION EXPOSURE TO INTERVENTIONAL ECHOCARDIOGRAPHERS DURING PERCUTANEOUS MITRAL VALVE REPAIR AND LEFT ATRIAL APPENDAGE CLOSURE
Authors: Lahdan Refahiyat, Jose Mariano Tan, Michael McNamara, Jeffrey Decker, Stacie Vanoosterhout, Duane Berkompas, William Merhi, Musa Dahu, Jessica Parker, Ryan Madder
Journal: Journal of the American College of Cardiology (2020)
TRANSCATHETER AORTIC VALVE REPLACEMENT IMPROVES THE QUALITY OF LIFE FOR PATIENTS WITH SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Authors: Cornelius Dyke, Mitchell Sand, Andrew B. Brown, Andrew Pasek, Donelle Staebler, Venkatkirin Kanchustambham, Ishmael Bekdesh, Thomas Haldis
Journal: Journal of the American College of Cardiology (2020)
CHALLENGES IN CHOLESTEROL MANAGEMENT IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM PATIENT AND PHYSICIAN SURVEYS IN THE GOULD STUDY
Authors: Suzanne Arnold, James de Lemos, Deepak Bhatt, Yuyin Liu, Robert S. Rosenson, Christie M. Ballantyne, Katherine Mues, Shushama Alam, Christopher P. Cannon, Mikhail Kosiborod
Journal: Journal of the American College of Cardiology (2020)
Skin damage among health care workers managing coronavirus disease-2019
Authors: Jiajia Lan, Zexing Song, Xiaoping Miao, Hang Li, Yan Li, Liyun Dong, Jing Yang, Xiangjie An, Yamin Zhang, Liu Yang, Nuoya Zhou, Liu Yang, Jun Li, JingJiang Cao, Jianxiu Wang, Juan Tao
Journal: Journal of the American Academy of Dermatology (2020)
Combination therapy of docetaxel, carboplatin or paclitaxel, carboplatin for patients with metastatic/recurrent carcinoma of the head and neck (SCCHN)
Authors: A. Bickmann, M. Holzgraefe, M. Wolf, M. Schröder
Journal: Journal of Clinical Oncology (2006)

5576 Background: The five-year survival for patients with recurrent disease has not been significantly increased in the last years. Despite aggressive initial management of the primary tumor, patients suffer from locoregional recurrence in up to 50% and distant metastasis is seen in about 25% of cases. Materials and Methods: 96 patients with recurrent or metastatic carcinoma of the head and neck received therapy as follows. From August 1996 to May 2000, 52 patients received chemotherapy with paclitaxel 100 mg/m 2 in combination with carboplatin AUC2. Between May 2000 and October 2004, 44 patients with recurrent or metastatic disease were treated with docetaxel 35 mg/m 2 in combination with carboplatin AUC2. Both chemotherapy regimens were administered weekly for a maximum of six cycles. Results: Most of the patients underwent a combination first line therapy with CT/Surg/RT (48%/47.7%) or CT/RT (36%/23%) before suffering from rec. disease. After recurrence local, regional or distant, we observed 9.6% complete response for the combination-therapy with paclitaxel/carboplatin and 25% with docetaxel/carboplatin, partial response in 38.5% and 34.1% of the patients, yielding an overall response rate of 48.1% with weekly paclitaxel/carboplatin and 59.1% with weekly docetaxel/carboplatin. Stable disease was documented for 25% of the patients treated with paclitaxel/carboplatin and 18.2% after treatment with docetaxel/carboplatin. Median survival was measured after first diagnosis of recurrence or metastatic disease. We observed a median survival of 10.9 month for the group treated with paclitaxel/carboplatin and 37 month for patients treated with docetaxel/carboplatin. Therapy with both treatment-options was well tolerated, all 96 patients received six cycles. Most frequent toxicity was leucopenia (Grade I/II/III: paclitaxel 12%/27%/15%; docetaxel 25%/23%/16%). Conclusions: Chemotherapy for recurrent carcinoma of the head and neck with weekly docetaxel/carboplatin is well tolerated and effective. The toxicitiy profile makes this combination favourable for an outpatient setting. No significant financial relationships to disclose.
Hematopoietic cell transplantation for refractory acute myeloid leukemia.
Authors: Annie P. Im, Navkiranjit K. Gill, Diana E. Cunningham, Mounzer E. Agha, Jing-Zhou Hou, Robert Redner, Michael Boyiadzis
Journal: Journal of Clinical Oncology (2013)

7059 Background: Hematopoietic cell transplantation (HCT) can be curative for patients with AML refractory to chemotherapy or re-induction after relapse. However, the role of HCT in this setting remains unclear. Our aim was to evaluate outcomes of HCT in these patients, and determine factors that may be predictive of complete remission (CR)/complete remission with incomplete count recovery (CRi) and overall survival (OS). Methods: Patients with relapsed AML who did not respond to re-induction or with primary induction failure (PIF) who received allogeneic HCT at University of Pittsburgh Cancer Institute 2000-2012 were identified. CR/CRi rates were calculated at day 30 and 100, and 3-year OS was determined using Kaplan Meier method. Cox proportional hazards regression was used to examine associations between factors of interest, and OS and CR/CRi. These included gender, age, relapse or PIF, 1° or 2° AML, cytogenetic risk, duration of CR1 (patients in relapse), performance status, number of induction cycles, circulating blasts, percentage of bone marrow (BM) blasts prior to HCT, matched unrelated or sibling donor, donor-recipient CMV status, and acute GVHD. Results: The study cohort consisted of 71 patients (median age 44 years, range 19-64) who underwent allogeneic HCT for refractory AML (relapse n=35, PIF n=36). At day 30, CR was 31% and CRi was 49%, for total 80% response rate. At day 100, 51% remained in CR/CRi. CR/CRi was associated with younger age (HR 1.26, p&lt;0.001) and lower percentage BM blasts (HR 1.03, p=0.026). Three-year OS was 12.3% (5.6-21.8), and median OS was 0.57 years (0.35-0.75). Lower OS was associated with matched unrelated versus sibling donor (HR 1.74, 1.02-2.96) and older age (p&lt;0.06). Of the 60 patients who were deceased, 38.6% died from progressive leukemia. Conclusions: Despite high CR/CRi rates after HCT for refractory AML, 3-year OS was low. Age and percentage BM blasts were significantly associated with CR/CRi. Only sibling donor was significantly associated with OS, though there was a trend for age. Though patients with refractory AML represent a high-risk group to undergo HCT, the high response rate through day 100 with subsequent disease-related mortality suggests a role for maintenance after HCT in this population.
PREDICTING CARDIAC STRUCTURAL AND FUNCTIONAL IMPROVEMENT INDUCED BY MECHANICAL UNLOADING IN CHRONIC HEART FAILURE: A DERIVATION-VALIDATION MULTICENTER STUDY
Authors: Iosif Taleb, Omar Wever-Pinzon, Abdallah Kfoury, William Caine, Josef Stehlik, Stephen McKellar, Rami Alharethi, Antigoni Koliopoulou, James C. Fang, Craig Selzman, Palak Shah, Ramesh Singh, Mitchell Psotka, Wei Zhu, Mark S. Slaughter, Emma Birks, Stephen Koenig, Manreet Kanwar, Maya Guglin, John Kotter, Kenneth Campbell, Andrija Vidic, Nirav Raval, Scott Silvestry, Stavros Drakos
Journal: Journal of the American College of Cardiology (2020)
A META-ANALYSIS OF BEMPEDOIC ACID FOR DYSLIPIDEMIA IN STATIN-INTOLERANT PATIENTS
Authors: Amanda Fernandes, Gilson Fernandes, Leonardo Mees Knijnik, Manuel Rivera Maza, Jorge Penalver, Rhanderson Cardoso, Carlos Enrique Alfonso, Eduardo De Marchena, Mauricio G. Cohen, Carl Orringer
Journal: Journal of the American College of Cardiology (2020)
Ultraplexing: increasing the efficiency of long-read sequencing for hybrid assembly with k-mer-based multiplexing
Authors: Alexander T. Dilthey, Sebastian A. Meyer, Achim J. Kaasch
Journal: Genome biology (2020)

Abstract Hybrid genome assembly has emerged as an important technique in bacterial genomics, but cost and labor requirements limit large-scale application. We present Ultraplexing, a method to improve per-sample sequencing cost and hands-on time of Nanopore sequencing for hybrid assembly by at least 50% compared to molecular barcoding while maintaining high assembly quality. Ultraplexing requires the availability of Illumina data and uses inter-sample genetic variability to assign reads to isolates, which obviates the need for molecular barcoding. Thus, Ultraplexing can enable significant sequencing and labor cost reductions in large-scale bacterial genome projects.
COMPARISON OF EARLY VERSUS DELAYED CORONARY ANGIOGRAPHY IN OUT-OF-HOSPITAL CARDIAC ARREST WITHOUT ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Muhammad Khalid, Ghulam Murtaza, Muhammad Talha Ayub, Varun Kohli, Rajesh Sachdeva, Gautam Kumar, Rupak Desai, Timir K. Paul
Journal: Journal of the American College of Cardiology (2020)
TARGETED TEMPERATURE MANAGEMENT IN SURVIVALS OF CARDIAC ARREST WITH NON-SHOCKABLE RHYTHMS: A META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS
Authors: Mohammed Osman, Sean R. Regner, Muhammad Bilal Munir, Khansa Osman, Mina Benjamin, Babikir Kheiri, Paul McCarthy, Sudarshan Balla, Christopher Bianco
Journal: Journal of the American College of Cardiology (2020)
Metformin limits osteoarthritis development and progression through activation of AMPK signalling
Authors: Jun Li, Bin Zhang, Wei-Xiao Liu, Ke Lu, Haobo Pan, Tingyu Wang, Chun-do Oh, Dan Yi, Jian Huang, Lan Zhao, Guangzhi Ning, Cong Xing, Guozhi Xiao, Ru Liu-Bryan, Shiqing Feng, Di Chen
Journal: Annals of the Rheumatic Diseases (2020)

<h3>Objectives</h3> In this study, we aim to determine the effect of metformin on osteoarthritis (OA) development and progression. <h3>Methods</h3> Destabilisation of the medial meniscus (DMM) surgery was performed in 10-week-old wild type and AMP-activated protein kinase (AMPK)α1 knockout (KO) mice. Metformin (4 mg/day in drinking water) was given, commencing either 2 weeks before or 2 weeks after DMM surgery. Mice were sacrificed 6 and 12 weeks after DMM surgery. OA phenotype was analysed by micro-computerised tomography (μCT), histology and pain-related behaviour tests. AMPKα1 (catalytic alpha subunit of AMPK) expression was examined by immunohistochemistry and immunofluorescence analyses. The OA phenotype was also determined by μCT and MRI in non-human primates. <h3>Results</h3> Metformin upregulated phosphorylated and total AMPK expression in articular cartilage tissue. Mild and more severe cartilage degeneration was observed at 6 and 12 weeks after DMM surgery, evidenced by markedly increased Osteoarthritis Research Society International scores, as well as reduced cartilage areas. The administration of metformin, commencing either before or after DMM surgery, caused significant reduction in cartilage degradation. Prominent synovial hyperplasia and osteophyte formation were observed at both 6 and 12 weeks after DMM surgery; these were significantly inhibited by treatment with metformin either before or after DMM surgery. The protective effects of metformin on OA development were not observed in AMPKα1 KO mice, suggesting that the chondroprotective effect of metformin is mediated by AMPK signalling. In addition, we demonstrated that treatment with metformin could also protect from OA progression in a partial medial meniscectomy animal model in non-human primates. <h3>Conclusions</h3> The present study suggests that metformin, administered shortly after joint injury, can limit OA development and progression in injury-induced OA animal models.
CONCORDANCE BETWEEN THE DIAGNOSIS OF HYPERTENSION BY OFFICE BLOOD PRESSURE AND HOME BLOOD PRESSURE MONITORING IN A FAMILY HEALTH CARE UNIT IN RIO DE JANEIRO, BRAZIL: LAPARC COHORT STUDY
Authors: Rafael Bellotti, Maria Antonia Oakim Mourão, Daniella Gomes Barbalho, Josimeiry Vitoria Cirilo Morais, Amanda Oliveira da Silva, Vinicius Leiria Teixeira Louzada, Daniela Fiuza Gomes Monteiro, Elizabeth Silaid Muxfeldt
Journal: Journal of the American College of Cardiology (2020)
SUBCLINICAL PULMONARY CONGESTION: A SILENT AND PREVALENT KILLER AT HEART FAILURE DISCHARGE
Authors: Jesus Alvarez-Garcia, Mercedes Rivas-Lasarte, Alba Maestro Benedicto, Juan Fernandez Martinez, Laura Lopez Lopez, Sonia Mirabet Perez, Vicens Brossa, Nuria Mesado, Maria Jose Pirla, Joan Cinca, Eulalia Roig, Alessandro Sionis Green
Journal: Journal of the American College of Cardiology (2020)
Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children
Authors: Yun-Han Wang, Viktor Wintzell, Jonas F. Ludvigsson, Henrik Svanström, Björn Pasternak
Journal: JAMA Pediatrics (2020)

<h3>Importance</h3> Proton pump inhibitor (PPI) use has been linked to increased risk of fracture in adults. Despite a trend in prescription of PPIs in children, there is scarce evidence regarding this safety concern in pediatric patients. <h3>Objective</h3> To evaluate the association between PPI use and risk of fracture in children. <h3>Design</h3> This nationwide register-based cohort study included data from Sweden from July 2006 to December 2016. Children younger than 18 years who initiated PPI use were matched on propensity score and age with those who did not initiate PPI use. <h3>Exposure</h3> Initiation of PPI use. <h3>Main Outcomes and Measures</h3> Cox regression was adopted to estimate hazard ratios (HRs) for a first fracture of any type and 5 subtypes of fracture, with follow-up for up to 5 years. To address potential residual confounding, high-dimensional propensity score matching and a direct comparison with histamine-2 receptor antagonists were performed. <h3>Results</h3> There were a total of 115 933 pairs of children included. During a mean (SD) of 2.2 (1.6) years of follow-up, 5354 and 4568 cases of any fracture occurred among those who initiated PPIs vs those who did not, respectively (20.2 vs 18.3 events per 1000 person-years; hazard ratio [HR], 1.11 [95% CI, 1.06-1.15]). Use of PPIs was associated with increased risk of upper-limb fracture (HR, 1.08 [95% CI, 1.03-1.13]), lower-limb fracture (HR, 1.19 [95% CI, 1.10-1.29]), and other fractures (HR, 1.51 [95% CI, 1.16-1.97]) but not head fracture (HR, 0.93 [95% CI, 0.76-1.13]) or spine fracture (HR, 1.31 [95% CI, 0.95-1.81]). The HRs for fracture according to cumulative duration of PPI use were 1.08 (95% CI, 1.03-1.13) for 30 days or less, 1.14 (95% CI, 1.09-1.20) for 31 to 364 days, and 1.34 (95% CI, 1.13-1.58) for 365 days or more. The association was consistent in most sensitivity analyses, including high-dimensional propensity score matching (HR, 1.10 [95% CI, 1.06-1.15]), although the analysis of PPI vs histamine-2 receptor antagonist did not reach statistical significance (HR, 1.06 [95% CI, 0.97-1.15]). <h3>Conclusions and Relevance</h3> In this large pediatric cohort, PPI use was associated with a small but significant increased risk of any fracture. Risk of fracture should be taken into account when weighing the benefits and risks of PPI treatment in children.
LONG TERM CLINICAL OUTCOMES AFTER IMPLANTATION OF ABSORB BVS IN A REAL WORLD SETTING, WITH PRE DILATATION AND GUIDED BY INTRAVASCULAR IMAGING
Authors: Sergio Tarbine, Costantino R. Costantini, Costantino Ortiz Costantini, Marcelo Freitas, Marcos Denk, Rafael Macedo, Marcio Luize, Joao Folador
Journal: Journal of the American College of Cardiology (2020)
MULTIMODALITY IMAGING IN EVALUATION OF COMPLICATIONS OF MYOCARDIAL INFARCTION: IS IT AN ANEURYSM, PSEUDANEURYSM, OR NEITHER?
Authors: David Houff, Renuka Jain, Mirza Baig, Mahmoud Ali, John Crouch, Patrycja Galazka, Jayant Khitha
Journal: Journal of the American College of Cardiology (2020)
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
Authors: Orit Itzhaki, Elad Jacoby, Abraham Nissani, Michal Levi, Arnon Nagler, Adva Kubi, Karin Brezinger, Hadar Brayer, Li-at Zeltzer, Meir Rozenbaum, Helly Vernitsky, Gal Markel, Amos Toren, Abraham Avigdor, Jacob Schachter, Michal J Besser
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background CD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, we initiated a clinical trial with in-house produced CD19 CAR-T cells with a CD28 co-stimulatory domain. We analyzed, for the first time, differences in production features and phenotype between ALL and NHL patients. Methods Non-cryopreserved CAR-T cells were produced from patients’ peripheral blood mononuclear cells within 9 to 10 days. 93 patients with r/r ALL and NHL were enrolled under the same study. CAR-T cells of ALL and NHL patients were produced simultaneously, allowing the head-to-head comparison. Results All patients were heavily pretreated. Three patients dropped out from the study due to clinical deterioration (n=2) or production failure (n=1). Cells of ALL patients (n=37) expanded significantly better and contained more CAR-T cells than of NHL patients (n=53). Young age had a positive impact on the proliferation capacity. The infusion products from ALL patients contained significantly more naïve CAR-T cells and a significantly higher expression of the chemokine receptor CXCR3. PD-1, LAG-3, TIM-3, and CD28 were equally expressed. 100% of ALL patients and 94% of NHL patients received the target dose of 1×10e6 CAR-T/kg. The overall response rate was 84% (30/36) in ALL and 62% (32/52) in NHL. We further compared CAR-T cell infusion products to tumor infiltrating lymphocytes (TIL), another common type of T cell therapy, mainly clinically effective in solid tumors. CAR-T cells contained significantly more naïve T cells and central memory T cells and significantly less CCR5 compared to TIL infusion products. Conclusions The in-house production of CAR-T cells is highly efficient and fast. Clinical response rate is high. CAR-T cells can be successfully produced for 99% of patients in just 9 to 10 days. Cells derived from ALL patients demonstrate a higher proliferation rate and contain higher frequencies of CAR-T cells and naïve T cells than of NHL patients. In addition, understanding the differences between CAR-T and TIL infusion products, may provide an angle to develop CAR-T cells for the treatment of solid tumors in the future. Trial registration number ClinicalTrials.gov; CAR-T: NCT02772198 , First posted: May 13, 2016; TIL: NCT00287131 , First posted: February 6, 2006.
Pharmacokinetic analyses of vorinostat in patients with metastatic soft tissue sarcoma.
Authors: Thomas Schmitt, Bianca Andres, Lu Liu, Margarete Leisen, Anthony D Ho, Juergen Burhenne, Gerd Mikus, Gerlinde Egerer
Journal: Journal of Clinical Oncology (2012)

10041^ Background: New treatment options for patients with metastatic soft tissue sarcoma (STS) are urgently needed. Preclinical studies suggest activity of vorinostat (V), a histone desacetylase (HDAC) inhibitor, in STS. Methods: We initiated a multicenter, open-label, non-randomized phase II trial (SAHA-I, NCT00918489) to investigate efficacy and safety of V in patients with metastatic STS failing 1°-line anthracycline-based CTX. Patients were treated with V 400 mg po QD for 28 days followed by a therapy-free period of 7 days. Blood samples for pharmacokinetic (PK) analyses were collected on day 7 of treatment cycle 1. Samples were acquired before and 30, 60, 90, 120, 240, 360, and 480 minutes after oral administration of V. Plasma- and intracellular concentration of V in peripheral blood mononuclear cells (PBMCs) was determined by mass spectrometry. Statistical differences were assessed by Wilcoxon matched-pairs signed rank test. This trial is ongoing. Results: Data on PK was available for n=8 subjects (male=4, female=4, median age=62 years). In plasma samples, mean C max (maximum concentration), t max (time to reach max. concentration), AUC (area under the plasma-concentration time curve), t 1/2 (elimination half-life) and Cl/F (apparent total clearance) were 350 ng/mL, 101 min, 71.1 min*µg/mL, 103 min and 5903 mL/min. The corresponding parameters in PBMCs were 558 ng/mL, 97.5 min, 208.4 min*µg/mL, 286 min and 2475 mL/min, respectively.The AUC plasma/PBMC ratio was 2.93, indicating accumulation of V in PBMCs. Differences in AUC (p=.008) and t 1/2 (p=.01) reached statistical significance. Conclusions: Interestingly, significantly higher concentrations of V were achieved in PBMCs andelimination half-life was prolonged compared to plasma. These results suggest potent intracellular activity of V.
IMPACT OF NONALCOHOLIC FATTY LIVER DISEASE ON ARRHYTHMIA RECURRENCE FOLLOWING ATRIAL FIBRILLATION ABLATION
Authors: Eoin Donnellan, Oussama Wazni, Mohamed Kanj, Daniel Cantillon, Divyang Patel, Kevin Trulock, Mohamed Elshazly, Arshneel Kochar, Joshua Cohen, Ayman Hussein, Bryan Baranowski, Brian P. Griffin, Wael A. Jaber, Walid I. Saliba
Journal: Journal of the American College of Cardiology (2020)
PATIENT REPORTED OUTCOMES CAN BE PREDICTED BY CHANGE IN LEFT ATRIAL PRESSURE AND NOT CHANGE OF TRANSMITRAL GRADIENT FOLLOWING MITRACLIP
Authors: Keniel F. Pierre, Demilade Adedinsewo, Mohammed Al-Hijji, Mohamad Alkhouli, Susie Sennhauser, Pragnesh Parikh, Fnu N. Salwa, Charanjit S. Rihal, Peter Pollak, Abdallah El Sabbagh
Journal: Journal of the American College of Cardiology (2020)